(thirdQuint)The Safety, Tolerability and Efficacy of LP-10 With Placebo in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis.

 This is a multi-center, dose-ranging, placebo-controlled, double-blind, randomized study including male and female subjects with refractory moderate to severe hemorrhagic cystitis as determined by a physician.

 A total of up to 18 subjects are anticipated and will be enrolled in study sites in the United States.

 Enrollment is expected to be completed within one year of initiating the study.

 The proposed trial will recruit 18 subjects in a dose-escalation trial where 6 subjects will be allocated into each one of three groups.

.

 The Safety, Tolerability and Efficacy of LP-10 With Placebo in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis@highlight

The purpose of this study is to assess the safety and tolerability of three doses of LP-10 (intravesical tacrolimus) compared to placebo.

 Eighteen subjects meeting the inclusion and exclusion criteria will be enrolled and treated in a prospective, doubleblind, randomized, placebo controlled, and multicenter trial with LP-10.

 The proposed trial will recruit 18 subjects in a dose-escalation trial where 6 subjects will be allocated into each one of three groups.

